Abstract

Irrespective of sex and age, cancer is the leading cause of mortality around the globe. Therapeutic incompliance, unwanted effects, and economic burdens imparted by cancer treatments, are primary health challenges. The heritable features in gene expression that are propagated through cell division and contribute to cellular identity without a change in DNA sequence are considered epigenetic characteristics and agents that could interfere with these features and are regarded as potential therapeutic targets. The genetic modification accounts for the recurrence and uncontrolled changes in the physiology of cancer cells. This review focuses on plant-derived flavonoids as a therapeutic tool for cancer, attributed to their ability for epigenetic regulation of cancer pathogenesis. The epigenetic mechanisms of various classes of flavonoids including flavonols, flavones, isoflavones, flavanones, flavan-3-ols, and anthocyanidins, such as cyanidin, delphinidin, and pelargonidin, are discussed. The outstanding results of preclinical studies encourage researchers to design several clinical trials on various flavonoids to ascertain their clinical strength in the treatment of different cancers. The results of such studies will define the clinical fate of these agents in future.

摘要

不论性别和年龄，癌症都是全球死亡的主要原因。主要的健康挑战是治疗不依从，不良影响以及癌症治疗带来的经济负担。通过细胞分裂传播并在不改变DNA序列的情况下促进细胞身份的基因表达中的可遗传特征被认为是表观遗传学特征，并且可以干扰这些特征的试剂被认为是潜在的治疗靶标。基因修饰解释了癌细胞生理学的复发和不受控制的变化。这篇综述着重于植物类黄酮作为癌症的治疗工具，这归因于它们对癌症发病机制进行表观遗传调控的能力。讨论了各种类黄酮的表观遗传机制，包括黄酮醇，黄酮，异黄酮，黄烷酮，黄烷-3-醇和花青素，例如花青素，德尔菲尼丁和pelargonidin。临床前研究的杰出成果鼓励研究人员针对各种类黄酮进行多项临床试验，以确定其在不同癌症治疗中的临床强度。这些研究的结果将确定这些药物在未来的临床命运。